Fimmcyte
Therapeutics
Read moreOn this page, you can explore the sponsored tracks BII runs in collaboration with relevant industry collaborators. By collaborating with industrial players, BII extends its offerings to early-stage start-ups by providing even better access to commercial paths and industry-specific knowledge.
The Reproductive Medicine and Maternal Health Track
Through the Reproductive Medicine and Maternal Health Track, Ferring Pharmaceuticals A/S supports BII to source and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine. This is a unique opportunity for applicants to get direct early access to extensive expertise and advice from a key industry player.
Our focus areas
We are looking for therapeutics or device solutions within the following areas:
If your project does not fall under these topics, check out the other topics supported in our women’s health initiative here.
Funding opportunities:
The Reproductive Medicine and Maternal Health Track supports applicants across BII’s programs:
Venture Lab
The Venture Lab program combines business acceleration, scientific, and team development and includes a EUR 500,000 risk-free convertible loan.
We are looking for projects with evidence-based ideas and a clear understanding of unique value propositions. Applicants can be early-stage startups or researchers looking to take their research to a translational stage and build a start-up.
Venture Lab start-ups also have the exclusive opportunity to apply for follow-on funding through the Venture House program – an 18-month program offering add-on funding of 10M DKK (1.3M EUR).
Read more about the program and apply for Venture Lab here
Bio Studio
The Bio Studio program supports world-leading entrepreneurial Principal Investigators (PIs) who want to translate their innovative research ideas into new solutions.
The PI will remain at their host institution, and each Bio Studio project will establish a team at BII in Copenhagen. Bio Studio projects will be supported by a tailored program to develop the entrepreneurial and commercial competencies of the team and by dedicated BII anchors to help guide project progression.
Projects run for up to 3 years, and the funding is awarded in sequential 1-year in-kind grants of up to DKK 7.8M (EUR 1M) per year. The goal of each project is to create a viable startup that can raise Seed or Series A financing by the end of the three years.
Read more on the Bio Studio page here.
The women’s health start-up Fimmcyte has already been supported under this track. Fimmcyte seeks to cure endometriosis, starting with a first step toward non-hormonal treatment of late-stage endometriosis. Read more about the first Ferring-sponsored project here.
Developing the first disease-modifying treatment for endometriosis.